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The decision of primary care providers to initiate treatment for attention-deficit/hyperactivity 
disorder (ADHD) in child and adolescent populations is a difficult choice that will be 
encountered often. ADHD is the most chronic health condition affecting school-aged children, 
with a prevalence of 8% in children and youth.1,2
 
Beyond academic underachievement and 
increased risk for accidental injury, children with ADHD may experience troublesome 
interpersonal relationships with family members and peers that contribute to the development of 
low self-esteem. More importantly, children left untreated for ADHD are at risk of developing 
substance abuse. Assessment, management, and treatment of ADHD can improve the educational 
and psychosocial development of most afflicted children and youth.3,4  
The American Academy of Pediatrics (AAP) recognizes that younger ages, coexisting 
conditions, and other concerns make the decision to treat increasingly pertinent, yet difficult for 
outpatient providers to perform.5 Specifically, intellectual disability, autistic spectrum disorder, 
moderate to severe sensory deficits, and physical, emotional, or sexual abuse, represent patient 
populations that would benefit from specialist referral or collaboration (see Table 1). There is 
also a high prevalence of coexisting conditions such as Oppositional Defiant Disorder (ODD) 
(35%), mood disorder (18%), anxiety disorder (25%), and learning disabilities (12-60%), which 
require evaluation, but do not preclude treatment for ADHD if diagnostically present.6 
The aim of this article is to provide a synopsis of the recommended changes and process of 
care algorithm developed by the AAP Subcommittee on Attention-Deficit/Hyperactivity 
Disorder, Steering Committee on Quality Improvement and Management, recently developed to 
streamline the diagnosis and treatment of ADHD by either family physicians or pediatricians on 
an outpatient basis.5 
 
Table 1. Coexisting conditions to be aware of when evaluating and diagnosis ADHD. 
 Mood and 
Behavior 
Physical Developmental Situational 
Coexisting 
Conditions 
Anxiety Sleep Disorder Learning Disorder Adjustment 
Depression Seizure Disorder 
Language 
Disorder Abuse 
Oppositional 
Defiance 
Disorder 
Tics Disorder Autism Spectrum Stress 
Conduct 
Disorder 
Hearing 
Deficits 
Intellectual 
Disorder Substance 
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Guideline Revisions 
Previously, the American Academy of Family Physicians (AAFP) had utilized the set of 
guidelines established by the AAP for assessment and diagnosis of school-aged children with 
ADHD, most recently from 2001.6 The former recommendations were applicable to an age range 
from six to twelve years, meeting the criteria of ADHD according to DSM-IV-TR,7 evident in 
various settings documenting the degree of functional impairment, core symptoms and duration, 
assessment for coexisting conditions, and diagnostic tests not routinely indicated for diagnosis of 
ADHD but helpful with evaluation for comorbid disease.6 The recommendations have been 
updated by the Subcommittee which is comprised of the AAP in collaboration with a 
subcommittee made up of primary care and developmental behavioral pediatricians, members of 
the American Academy of Child and Adolescent Psychiatry, Child Neurology Society, Society 
for Pediatric Psychology, National Association of School Psychologists, the Society for 
Developmental and Behavioral Pediatrics, the American Academy of Family Physicians, 
Children and Adults with Attention-Deficit/Hyperactivity Disorder, along with epidemiologists 
from Center for Disease Control and Prevention.5 Most noteworthy is the effort given to provide 
evidence based updates to the guidelines focusing on current treatment approaches, safety 
concerns, and practicality in a busy outpatient setting. The key action statements are summarized 
below in Table 2.  The key action statements of the new guidelines5 are:  
• Evaluation for any patient, 4-18 years of age, who has symptoms suggestive of ADHD is 
strongly recommended (quality of evidence B). 
• The DSM-IV-TR7 criteria for ADHD, regardless of subtype, must be satisfied based on 
reports from two settings, usually parents and teachers (strongly recommended; quality of 
evidence B). 
• Assessment for coexisting conditions including physical, behavioral, developmental, and 
situational (stress, adjustment, abuse) is strongly recommended (quality of evidence B). 
• Perception of ADHD must recognize affected patients as having special health care needs 
that qualifies as a chronic condition (strongly recommended; quality of evidence B). 
• Age specific treatments exist, specifically preschool children, 4-5 years of age. Receive 
behavioral therapy as first line treatment is strongly recommended (quality of evidence 
A) while possible use of US Food and Drug Administration (FDA) approved medications 
is recommended (quality of evidence B). Elementary-aged children 6-11 years of age 
receive FDA-approved medications for treatment of ADHD (strongly recommended; 
quality of evidence A), along with parent and/or teacher administered behavioral therapy 
(quality of evidence B). Adolescents 12-18 years of age receive FDA-approved 
medications for treatment of ADHD (strongly recommended; quality of evidence A) and 
behavioral therapy is recommended (quality of evidence C). 
• Primary care physicians should titrate FDA approved medications for treatment of 
ADHD to maximize benefits yet minimize adverse effects (strongly recommended; 
quality of evidence B). 
 
Process-of-care Algorithm 
The AAP has set forth a treatment and assessment algorithm to streamline the decision 
making process when working with school aged children with concerns of ADHD, with a 
summary provided in Figure 1. The sentiments of the process-of-care algorithm are paraphrased 
in Table 3. Of importance, the process outlined in the algorithm is not intended to be completed 
in one office visit, but correct application depends on the provider experience and comfort level, 
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Table 2. Strongly recommended key action statements for the new guidelines regarding 
evaluation, diagnosis, and treatment of ADHD, except for behavioral therapy in ages greater than 
11 years, which is recommended with a quality of evidence C. 
 
 
Key Statement of Guideline Additional Consideration 
Expanded Age 
Range 
Evaluation and treatment of 
ADHD is expanded to ages 4-
18 years old, no longer limited 
to 6-12 years old. 
ADHD must be diagnosed before 7 
years, unless history prior to cutoff 
reveals symptoms fulfilling criteria for 
diagnosis. 
Diagnostic 
Criteria 
Identification of DSM-IV-TR7 
symptoms reported from two 
settings (parents and teachers). 
Ensure validated DSM-IV-TR ADHD 
rating scales are utilized; consider mood 
and behavioral disturbances along with 
substance use. 
Coexisting 
Conditions 
Appropriately screen for 
conditions that coexist with 
ADHD (e.g., ODD, Tourette’s). 
Assess physical, behavioral, 
developmental, and situational 
conditions. 
Clinical 
Perception of 
ADHD 
Youth and children with ADHD 
have special health care needs. 
Management of ADHD patients should 
follow the principles of the chronic care 
model and the medical home. 
Age Determines 
First Line of 
Treatment 
Children less than 6 years old: 
behavioral treatment and 
possible FDA-approved 
medication.*  
First line medication is methylphenidate, 
with patient appropriate formulation. 
 
Children 6-11 years old: FDA-
approved medication and 
behavioral treatment. 
Second line medication is atomoxetine. 
 
Children and adolescents older 
than 11 years: FDA-approved 
medication and possible 
behavioral treatment. 
Third line and adjunctive treatments 
include guanfacine ER and clonidine 
ER. 
Titrate ADHD 
approved Rx 
for maximal 
benefit but 
minimize ADRs 
70% of ADHD patients respond 
with continued systematic trials 
of different therapies given 
adequate titrations over 3 to 7 
days prior to changing agents. 
Headaches, reduced appetite, decreased 
sleep, and reduced growth velocity in 
first two years. Rare risk of sudden 
cardiac death. Guanfacine has risk of 
hepatitis. 
*Decision to utilize FDA-approved medications in preschool children depends on severity of 
ADHD symptoms and duration. 
 
existing office resources and infrastructure acquainted with mental health surveillance and 
screening.8 All aspects of the diagnostic and treatment procedures must be documented in the 
patient's chart along with the use of rating scales at baseline to assess response to medications 
and provide objective reports to parents.9 In the Subcommittee's development of the process-of-
care algorithm for the assessment, diagnosis, and treatment of ADHD, occasionally there was 
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Figure 1. Modified ADHD process-of-care algorithm from the AAP.9 
 
insufficient evidence based data to support parts of the approach but these were supplemented 
with the utilization of expert opinion.5 
In a sensitive manner, office staff is recommended to inquire about the chief complaint to set 
an appointment that provides adequate time and resources to optimize the encounter. Prior to 
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Table 3. Outline of ADHD process-of-care algorithm from the AAP.9
 
Step Recommended Approach 
Before 
Appointment 
Identify reasons for appointment and schedule adequate time. 
Pre-exam questionnaires by patient, teachers, and parents. 
Obtain consent for school data, reports, etc. 
Evaluation 
Consider ADHD in any patients 4 to 18 years old with symptoms. 
History from family and teachers, with validated ADHD scales. 
History to include: onset and duration of symptoms, past medical, family, 
psychosocial, coexisting conditions, substance abuse, and report of function. 
Interview patient to determine their self-impression of function; observe their 
mood symptoms and behaviors, and to assess neurological function. 
Administer self-report instrument of ADHD in adolescents. 
Diagnosis 
6-9 inattentive symptoms and < 6 hyperactive/impulsive symptoms 
suggestive of ADHD/I (inattentive type). 
6-9 hyperactive/impulsive symptoms and < 6 inattentive symptoms 
suggestive of ADHD/HI (hyperactive-impulsive type). 
6-9 symptoms of both inattentive and hyperactive/impulsive is suggestive of 
ADHD/C (combined type). 
Less than 6 symptoms and/or failing to satisfy below criteria is suggestive of 
ADHD/NOS or Developmental Variation. 
Symptoms need to be present > 6 months, must be present in two settings, 
must be present prior to age of 7, and must coincide with significant 
impairment in social, academic, or occupational functioning. 
No Coexisting 
Conditions Treat according to guidelines based on patient's age. 
Coexisting 
Conditions 
Establish management team with collaboration with family, school, child, 
and other health care providers to establish treatment goals and strategy, with 
follow-up a minimum of twice a year once goals obtained. 
Developmental concerns may be treated depending on provider level of 
comfort, as both can improve with therapy, or referral for collaboration with 
mental health professional can be beneficial 
Behavioral or situational concerns may be treated depending on provider 
level of comfort, as both can improve with therapy, or referral for 
collaboration with mental health professional can be beneficial. 
Hold treatment for coexisting substance use until addiction recovery is 
ascertained or utilize less addictive medications such as adderall. 
Physical co-morbidities may be treated depending on provider level of 
comfort or seek consultation from neurology or respirology as required. 
Developmental 
Variation 
Provide education regarding concerns and triggers; maintain surveillance 
with regularly scheduled appointments. 
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attending the first appointment to assess for ADHD, parents should be asked to complete 
questionnaires regarding symptoms and level of functional impairment, obtain information from 
academic settings such as report cards, standardized testing, and psychoeducational assessments, 
along with signing consent for primary treatment teams to obtain and share information with 
academic institutions.9 Evaluation is required in any patient ages 4 to 18 years of age with 
symptoms suggestive of ADHD. Evaluation requires obtaining functional history of impairment 
from two settings, commonly parents and teachers, with use of validated ADHD scales whenever 
possible. These parties also should assist in provision of medical, family, developmental, 
psychosocial, and substance abuse history. To assess for coexisting conditions in adolescents, it 
is essential to be conscious of mood disorders, psychosocial stressors, or neurological conditions, 
and obtain the patient’s self-impression, sometimes requiring the use of self-reported 
instruments. 
In diagnosis of ADHD, the presence of core symptoms is essential.9 The presence of 6-9 
hyperactive/impulsive symptoms and less than six inattentive symptoms are required for 
ADHD/Hyperactive/Impulsive (HI) subtype diagnosis. The presence of 6-9 inattentive symptoms 
and less than six hyperactive/impulsive symptoms are required for ADHD/Inattentive (I) subtype 
diagnosis. Finally, the presence of 6-9 symptoms of both hyperactive/impulsive and inattentive 
features is indicative of ADHD/Combined (C) subtype. If there is presentation after age 7, years 
without symptoms in the history before this age, the duration of symptoms is less than six 
months, these features are not observed in two settings, or these symptoms do not provide 
functional impairment, then the diagnosis of ADHD cannot be made and the term of 
Developmental Variation is applied.9 If there is the presence of less than six symptoms of either 
subtypes or the patient fails to meet the qualifier remarks above, then the diagnosis of 
ADHD/NOS may be applied. Table 4 includes a list of ADHD subtype symptoms based 
generated from the DSM-5.10 Screening for coexisting conditions may be positive which could 
warrant the referral to appropriate services should the primary team feel uncomfortable treating 
ADHD under such circumstances. Beyond physical contributors such as hearing deficits or 
seizure, ADHD treatment may preclude treatment of anxiety or depression as these disorders 
often benefit from this approach.  
 
Discussion 
The new treatment guidelines5 are an extension of the previous action statements in 20016, 
but have utilized evidence based material to update these practices and provide more guidance 
for practitioners in a demanding outpatient setting. There will be features of the new guidelines 
that may generate questions from family and providers; however, it is essential to consider the 
long term outcomes of untreated ADHD. Parents of young children may have concerns regarding 
the assessment and possible treatment of ADHD in preschool age ranges, but there is evidence to 
support the early presentation and the acute benefits of treatment.11,12 For providers, it is 
important to note that most patients with ADHD will not display core symptoms during physical 
and mental status examinations placing significant weight on the description of features by 
family and teachers.13 It is critical that screening for addiction be conducted and that appropriate 
treatment be provided prior to the management of ADHD.14 To avoid long term consequences of 
ADHD, the chronic care model suggests ongoing care along with bidirectional communication 
with teachers, other mental health professionals, and the parents; an approach that has been 
validated in asthma patients.15,16 
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Table 4. ADHD subtype symptom requirements* adapted from DSM-5.10 
*Symptoms must have persisted for at least 6 months to a degree that is maladaptive and 
inconsistent with developmental level. Symptoms must occur prior to age 7 years and must occur 
in two settings. The disturbance must cause clinically significant distress or impairment in social, 
academic, or occupational functioning. 
 
The major concern with lack of treatment is the long term risks of poor academic 
achievements, inability to build beneficial relationships, poor executive function throughout life, 
substance abuse, and decreased self-esteem with risk of mood disorders.9 Methylphenidate is 
strongly recommended with a quality of evidence A, followed by atomoxetine, extended release 
guanfacine, and extended release clonidine, in that order, with strong recommendation and the 
quality of evidence A.5 Dextroamphetamine is the only ADHD medication approved for use in 
patients less than 6 years of age with insufficient evidence for safety, while there are more 
clinical studies with methylphenidate suggesting efficacy and safety.5,17 Treatment of preschool 
children with FDA-approved medications has been targeted toward patients with moderate to 
severe ADHD that has persisted more than nine months, has been refractory to behavioral 
therapy, all of which has been observed in two or more settings.17 A referral to a specialist for 
treatment of preschool children with moderate to severe symptoms would be reasonable should 
the primary care provider feel it warranted. Children of preschool ages have lower rates of 
metabolism thus lower dosages are recommended with regular titration as necessary. Guanfacine 
ER and clonidine ER are the only two medications that are FDA approved for adjunctive therapy 
in children 6 to 17 years old.18,19 
Common adverse effects of medication approved for ADHD include headache, decreased 
appetite, sleep disturbance, and decreased growth velocity of about 1-2 cm on average.20 There 
can be psychosis and hallucination with stimulant use, a rare occurrence, with one study showing 
a 1.48% rate of incidence.21 In patients younger than 6 years of age, there are reports of greater 
mood lability and dysphoria.17 Although there are case reports of stimulant-induced 
cardiovascular effects,22 along with the non-stimulant drug-induced myocardial infarction,23 
ADHD specialists from the European ADHD Guidelines Group, the European Network of 
Hyperkenetic Disorders, and pediatric cardiovascular specialists came to the conclusion that the 
Hyperactive/Impulsive Inattentive 
Fidgeting Seems not to listen 
Unable to remain seated No sustained attention 
Runs or climbs in inappropriate settings Poor attention to details or careless mistakes 
Difficulty with leisure activities Fails to finish tasks 
Seems to be “On the go” Poor organization 
Talks excessively Avoids tasks requiring attention 
Blurts out answers Loses things for tasks 
Unable to wait turn Easily distracted 
Interrupts or intrudes on others Forgetful 
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overall risk of sudden death in young individuals using ADHD medications does not exceed that 
of the general population.24 Children who suffer from ADHD had changes in heart rate 
variability that benefit from stimulant treatment.25 Overall, most reports in children and 
adolescents indicated rare occurrence of stimulant-induced cardiovascular adverse effects.26 The 
effect of stimulant use on sleep is not straightforward as it is multifactorial that includes the 
subtype of ADHD, the patient's pretreatment sleeping habits, the type of medication utilized, 
along with the duration, frequency, and formulation of the medication.27 The most common 
adverse event with stimulant medication is delayed sleep onset latency that ranges from 30 to 50 
minutes depending on the agent utilized.28,29  
Behavioral modification therapy often helps parents and teachers devise reward systems that 
encourage desired behavior along with elimination of unwanted traits.30-32 Beyond assisting 
parents to modify the home environment to benefit the child, it also builds parental awareness of 
triggers and helps children/patients regulate their own behaviors.5 The long term effects of 
behavioral therapy remain to be evaluated but incorporation of such strategies is essential under 
the chronic care model.33 Despite mixed reviews on the combined efficacy of medications and 
behavioral therapy, there is certainty that lower dosages are required, thus reducing the risk of 
adverse effects.34  
Ultimately the evaluation, diagnosis, and treatment of ADHD will be conducted by outpatient 
providers and the aim of the new guidelines, and this article, is to assist these treatment teams in 
such roles. There continues to be shortcomings based on limited information such as long term 
effects of medications in preschool populations, comparisons of different medications in the 
different age ranges, validated diagnostic tools, effectiveness of collaborative efforts, timelines 
for follow-ups, and approaches to increase adherence to treatments.5 However, there are 
advancements emerging such as computer aided evaluations35 along with off label administration 
of safety established neurological agents, which could aid substantially in the diagnosis and 
treatment of ADHD.36,37 More recently, electroencephalographic (EEG) studies showed fronto-
central theta-to-beta band activity ratios that displayed consistent abnormalities in patients with 
ADHD.38 Such neuro-feedback studies have shown application to ADHD in young adult 
populations.39 Meta-analyses showing EEG to have some prognostic utility40 leading the FDA to 
approve this three dimensional approach as a conjunctive tool in the diagnosis of ADHD in 
patients 6 to 17 years of age.41
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